Somatostatin: still a pharmaceutical defense weapon against post-ERCP pancreatitis? A 30-year story

• References

• 1 Borsch G, Bergbauer M, Nebel W et al. Der einflu von somatostatin auf die amylasepiegel und pankreatistrate nach ERCP. Med Welt 1984; 35: 109-112
• 2 Murray B, Carter R, Imrie C et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-1791
• 3 Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial or rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
• 4 Dumonceau JM, Andriulli A, Deviere J et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42: 503-515
• 5 Dumonceau JM, Andriulli A, Elmunzer BJ et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – updated June 2014. Endoscopy 2014; 46: 799-815
• 6 Katsinelos P, Fasoulas K, Paroutoglou G et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy 2012; 44: 53-59
• 7 Wang ZK, Yang YS, Cai FC et al. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial. Chin Med J (Engl) 2013; 126: 2403-2408
• 8 Concepción-Martín M, Gómez-Oliva C, Juanes A et al. Somatostatin for prevention of post-ERCP pancreatitis: a randomized, double-blind trial. Endoscopy 2014; 46: 851-856
• 9 Zhao LN, Yu T, Li CQ et al. Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients. Exp Ther Med 2014; 8: 509-514
• 10 Andriulli A, Leandro G, Niro G et al. Pharmacological treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51: 1-7
• 11 Rudin D, Kiss A, Wetz RV et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007; 22: 977-983
• 12 Andriulli A, Leandro G, Federici T et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 5: 624-632
• 13 Omata F, Deshpande G, Tokuda Y et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2010; 45: 885-895
• 14 Gullo L, Pezzilli R, Barbara L. Effect of somatostatin on plasma amino acid uptake by human pancreas. Gastroenterology 1989; 98: 732-736
• 15 Karalis K, Mastorakos G, Chrousos GP et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93: 2000-2006
• 16 Yuan Y, Gong Z, Lou K et al. Effects and mechanisms of somatostatin analogs on apoptosis of pancreatic acinar cells in acute pancreatitis in mice. J Gastroenterol Hepatol 2001; 16: 683-688
• 17 Lai KH, Lo GH, Cheng JS et al. Effect of somatostatin on the sphincter of Oddi in patients with acute non-biliary pancreatitis. Gut 2001; 49: 843-846
• 18 Bai Y, Xu R, Zhang XF et al. Prophylactic somatostatin can reduce the incidence of post-ERCP pancreatitis: multicenter randomized controlled trial. Endoscopy 2015; 47: 415-420
• 19 Shi QQ, Ning XY, Zhan LL et al. Placement of prophylactic pancreatic stents to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in high risk patients: a meta-analysis. World J Gastroenterol 2014; 20: 7040-7048